American College Of Surgeons - Inspiring Quality: Highest Standards, Better Outcomes

Session Code: PS308
Title: Novel Approaches to the Management of Advanced Pancreatic Cancer
Date and Time of Session: Wednesday, October 25: 9:45 am - 11:15 am
Description: An emerging strategy for borderline-resectable patients that are deemed ineligible for upfront surgery is neoadjuvant treatment in the form of chemotherapy with or without radiation. Such neoadjuvant strategies not only have the potential to downstage borderline-resectable disease to make R0 resection feasible, but they also allow for the early treatment of micrometastatic disease, delivery of chemotherapy to an undisturbed tumor, and biological assessment of tumor aggressiveness. For initially unresectable Locally Advanced Pancreatic Cancer (LAPC), neoadjuvant therapy should be offered as a bridge to potentially curative resection. This panel will focus on controversies in the management of this population of patients.
CME Credit Hours: 1.5
Webcast Package Available: Yes
Audio Package Available: Yes
Surgical Oncology (ONC), General Surgery (GEN)
Credit to Address ACS Accreditation/Verification Requirements:
Sponsored By:
Advisory Council for General Surgery
Program Participants:
Rebekah R. White, MD, FACS
Hong Jin Kim, MD, FACS
Speaker Introduction
Rebekah R. White, MD, FACS
Speaker Update on Chemotherapy for Locally Advanced Pancreatic Cancer
Tony R. Reid, MD
Speaker Novel Radiation Therapy Strategies for Locally Advanced Pancreatic Cancer
Theodore S. Hong, MD
Speaker Irreversible Electroporation for Locally Advanced Pancreatic Cancer
Robert C. G. Martin, MD, PhD, FACS
Speaker Iontophoresis for Delivery of Chemotherapy to Locally Advanced Pancreatic Cancer
Jen Jen Yeh, MD, FACS
Speaker Discussion
Hong Jin Kim, MD, FACS